Indications for: LOREEV XR
Anxiety disorders in adults who are receiving stable, evenly divided, 3 times daily dosing with lorazepam tabs.
Swallow whole or open cap and sprinkle contents onto applesauce (1 tbsp). Administer the 1st dose the day after the final dose of lorazepam tabs. Give once daily in the morning. Recommended once daily dose = the total daily dose of lorazepam tabs. For inadequate clinical response, concomitant UGT inhibitors: discontinue Loreev XR, switch to lorazepam tabs, and then adjust dosage.
LOREEV XR Contraindications:
Acute narrow-angle glaucoma.
Risk from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
LOREEV XR Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Therapy for >4 months. Discontinue if paradoxical reactions occur. Primary depressive disorder or psychosis: not recommended. Suicidal ideation (monitor). Compromised respiratory function (eg, respiratory depression, apnea); monitor closely. Reevaluate periodically. Monitor CBCs, LFTs during long-term therapy. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Change dose gradually. Write ℞ for smallest practical amount. Drug or alcohol abuse. Severe hepatic impairment and/or encephalopathy. Elderly. Neonates/infants (monitor). Pregnancy. Nursing mothers: not recommended.
LOREEV XR Classification:
LOREEV XR Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiates CNS depression with alcohol (avoid), clozapine, other CNS depressants; caution. May be potentiated by UGT inhibitors (eg, valproate, probenecid); if unavoidable, reduce dose (see Adult).
Sedation, dizziness, weakness, unsteadiness; withdrawal reactions, CNS depression.
Generic Drug Availability: